Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance of Simnotrelvir (SIM0417) in Healthy Chinese Males
NCT05475834Phase 1Completed
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Jul 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of simnotrelvir in coronavirus disease 2019 (COVID-19), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Total recovery of SIM0417-related substances in urine at 168 hours, Total recovery of SIM0417-related substances in feces at 168 hours and 3 more. Started Jul 2022; status: completed.
02
Drugs
simnotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05475834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05475834.